Exact Mass: 323.2283

Exact Mass Matches: 323.2283

Found 169 metabolites which its exact mass value is equals to given mass value 323.2283, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Lysergide

(6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide

C20H25N3O (323.1998)


Lysergic acid diethylamide is an ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine. It has a role as a hallucinogen, a serotonergic agonist and a dopamine agonist. It is an ergoline alkaloid, an organic heterotetracyclic compound and a monocarboxylic acid amide. It is functionally related to a lysergamide. D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D006213 - Hallucinogens C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist

   

N-Jasmonoylisoleucine

(2S,3S)-2-({1-hydroxy-2-[(1R,2R)-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]ethylidene}amino)-3-methylpentanoate

C18H29NO4 (323.2096)


N-Jasmonoylisoleucine belongs to the class of organic compounds known as isoleucine and derivatives. Isoleucine and derivatives are compounds containing isoleucine or a derivative thereof resulting from the reaction of isoleucine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. N-Jasmonoylisoleucine is an extremely weak basic (essentially neutral) compound (based on its pKa). N-Jasmonoylisoleucine is found in pulses. N-Jasmonoylisoleucine is isolated from Pinus mugo (dwarf mountain pine) and Vicia fab.

   

Lycofawcine

Lycopodium Base L

C18H29NO4 (323.2096)


   

Prodigiosin

Prodigiosine

C20H25N3O (323.1998)


A member of the class of tripyrroles that is a red-coloured pigment with antibiotic properties produced by Serratia marcescens. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents

   

Undeca-2,4,6-trienoylcarnitine

4-(trimethylazaniumyl)-3-(undeca-2,4,6-trienoyloxy)butanoate

C18H29NO4 (323.2096)


Undeca-2,4,6-trienoylcarnitine is an acylcarnitine. More specifically, it is an undeca-2,4,6-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undeca-2,4,6-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undeca-2,4,6-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undeca-2,5,8-trienoylcarnitine

4-(trimethylazaniumyl)-3-(undeca-2,5,8-trienoyloxy)butanoate

C18H29NO4 (323.2096)


Undeca-2,5,8-trienoylcarnitine is an acylcarnitine. More specifically, it is an undeca-2,5,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undeca-2,5,8-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undeca-2,5,8-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4E,6E)-Undeca-4,6,9-trienoylcarnitine

4-(trimethylazaniumyl)-3-(undeca-4,6,9-trienoyloxy)butanoate

C18H29NO4 (323.2096)


(4E,6E,9E)-Undeca-4,6,9-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4E,6E,9E)-undeca-4,6,9-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6E,9E)-Undeca-4,6,9-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4E,6E,9E)-Undeca-4,6,9-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Undeca-3,5,7-trienoylcarnitine

4-(trimethylazaniumyl)-3-(undeca-3,5,7-trienoyloxy)butanoate

C18H29NO4 (323.2096)


Undeca-3,5,7-trienoylcarnitine is an acylcarnitine. More specifically, it is an undeca-3,5,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undeca-3,5,7-trienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Undeca-3,5,7-trienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4,6-di-tert-butylphenol

2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4,6-di-tert-butylphenol

C20H25N3O (323.1998)


   

Cicloprolol

1-{4-[2-(cyclopropylmethoxy)ethoxy]phenoxy}-3-[(propan-2-yl)amino]propan-2-ol

C18H29NO4 (323.2096)


   

Lysergide

N,N-diethyl-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide

C20H25N3O (323.1998)


   

Prodigiosin

3-methoxy-2-[(5-methyl-4-pentyl-1H-pyrrol-2-yl)methylidene]-5-(1H-pyrrol-2-yl)-2H-pyrrole

C20H25N3O (323.1998)


   

3-Methoxy-2-[(5-methylidene-4-pentylpyrrol-2-ylidene)methyl]-5-(1H-pyrrol-2-yl)-1H-pyrrole

4-methoxy-5-[(5-methylidene-4-pentyl-2,5-dihydro-1H-pyrrol-2-ylidene)methyl]-1H,1H-2,2-bipyrrole

C20H25N3O (323.1998)


   

Carbazoquinocin E

Carbazoquinocin E

C21H25NO2 (323.1885)


   

Pumiliotoxin B

Pumiliotoxin B

C19H33NO3 (323.246)


   

Melophlin C

Melophlin C

C19H33NO3 (323.246)


   

Melophlin O

Melophlin O

C19H33NO3 (323.246)


   

CW 69D

3H-Carbazole-3,4(9H)-dione,Carbazoquinocin D

C21H25NO2 (323.1885)


   

Melophlin K

Melophlin K

C19H33NO3 (323.246)


   
   

Melophlin L

Melophlin L

C19H33NO3 (323.246)


   

Melophlin N

Melophlin N

C19H33NO3 (323.246)


   

Melophlin G

Melophlin G

C19H33NO3 (323.246)


   
   

2-(2H-Benzotriazol-2-yl)-4-(tert-butyl)-6-(sec-butyl)phenol

2-(2H-Benzotriazol-2-yl)-4-(tert-butyl)-6-(sec-butyl)phenol

C20H25N3O (323.1998)


   

UV Absorber UV-329

2-(2-hydroxy-5-tert-octylphenyl)benzotriazole

C20H25N3O (323.1998)


CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11720; ORIGINAL_PRECURSOR_SCAN_NO 11715 C1892 - Chemopreventive Agent > C851 - Sunscreen CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11762; ORIGINAL_PRECURSOR_SCAN_NO 11757 CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11782; ORIGINAL_PRECURSOR_SCAN_NO 11777 CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11824; ORIGINAL_PRECURSOR_SCAN_NO 11820 CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11837; ORIGINAL_PRECURSOR_SCAN_NO 11833 CONFIDENCE standard compound; INTERNAL_ID 722; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 11857; ORIGINAL_PRECURSOR_SCAN_NO 11853

   

(+)-allopumiliotoxin 323B|(7S,8R,8aS,6E)-7,8-Dihydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-hydroxy-4-octenylidene]octahydroindolizidine|allopumiliotoxin 323B

(+)-allopumiliotoxin 323B|(7S,8R,8aS,6E)-7,8-Dihydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-hydroxy-4-octenylidene]octahydroindolizidine|allopumiliotoxin 323B

C19H33NO3 (323.246)


   
   

3-methoxy-2-[(5-methyl-1-pentylpyrrol-2-yl)methylidene]-4-pyrrol-1-ylpyrrole

3-methoxy-2-[(5-methyl-1-pentylpyrrol-2-yl)methylidene]-4-pyrrol-1-ylpyrrole

C20H25N3O (323.1998)


   

melophlin B

melophlin B

C19H33NO3 (323.246)


   
   

pandamarilactonine-F

pandamarilactonine-F

C18H29NO4 (323.2096)


   

18-isothiocyanato-17-octadecenal

18-isothiocyanato-17-octadecenal

C19H33NOS (323.2283)


   

14,15-dehydro-holadienine

14,15-dehydro-holadienine

C22H29NO (323.2249)


   

sessilifoliamide D

sessilifoliamide D

C18H29NO4 (323.2096)


   

Carbazoquinocin D

Carbazoquinocin D

C21H25NO2 (323.1885)


   
   

4-methoxy-5-(5-methyl-4-pentyl-pyrrol-2-ylmethylene)-1H,5H-[2,2]bipyrrolyl|7-methoxy-1-methyl-2-pentyl-14H,16H-prodigiosene|Prodigiosin

4-methoxy-5-(5-methyl-4-pentyl-pyrrol-2-ylmethylene)-1H,5H-[2,2]bipyrrolyl|7-methoxy-1-methyl-2-pentyl-14H,16H-prodigiosene|Prodigiosin

C20H25N3O (323.1998)


   

3alpha-(3,4-dihydroxymyrtanoyloxy)tropane|8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3,4-dihydroxy-6,6-dimethylbicyclo[3.1.1]heptan-2-carboxylate|bonabiline A

3alpha-(3,4-dihydroxymyrtanoyloxy)tropane|8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3,4-dihydroxy-6,6-dimethylbicyclo[3.1.1]heptan-2-carboxylate|bonabiline A

C18H29NO4 (323.2096)


   
   

N-3-oxo-tetradec-7Z-enoyl-L-Homoserine lactone

N-3-oxo-tetradec-7Z-enoyl-L-Homoserine lactone

C18H29NO4 (323.2096)


   

piperidolate

piperidolate

C21H25NO2 (323.1885)


A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AA - Synthetic anticholinergics, esters with tertiary amino group C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Piperidolate is an antimuscarinic, inhibits intestinal cramp induced by acetylcholine (rats and dogs).

   

Jasmonic acid-isoleucine (JA-Ile)

Jasmonic acid-isoleucine (JA-Ile)

C18H29NO4 (323.2096)


   

lsd

lsd

C20H25N3O (323.1998)


CONFIDENCE standard compound; INTERNAL_ID 1625 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3688

   

Melophlin B/C/G/K/L/N/O

Melophlin B/C/G/K/L/N/O

C19H33NO3 (323.246)


   

Betaxolol(hydroxylation)

Betaxolol(hydroxylation)

C18H29NO4 (323.2096)


   

(7R,E)-8-((8S,Z)-8-hydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-4,7-dimethyloct-4-ene-2,3-diol

(7R,E)-8-((8S,Z)-8-hydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-4,7-dimethyloct-4-ene-2,3-diol

C19H33NO3 (323.246)


   

(7R,8R,E)-6-((2R,E)-6-hydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol

(7R,8R,E)-6-((2R,E)-6-hydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol

C19H33NO3 (323.246)


   

(7R,E)-8-((1S,Z)-1-hydroxyhexahydro-2H-quinolizin-3(4H)-ylidene)-4,7-dimethyloct-4-ene-2,3-diol

(7R,E)-8-((1S,Z)-1-hydroxyhexahydro-2H-quinolizin-3(4H)-ylidene)-4,7-dimethyloct-4-ene-2,3-diol

C19H33NO3 (323.246)


   

N-3-oxo-tetradec-7(Z)-enoyl-L-Homoserine lactone

3-oxo-N-[(3S)-tetrahydro-2-oxo-3-furanyl]-7-tetradecenamide

C18H29NO4 (323.2096)


   

N-Jasmonoylisoleucine

3-methyl-2-(2-{3-oxo-2-[(2E)-pent-2-en-1-yl]cyclopentyl}acetamido)pentanoic acid

C18H29NO4 (323.2096)


   

N-jasmonoyl-isoleucine

N-({(1R,2R)-3-Oxo-2-[(2Z)-Pent-2-En-1-Yl]cyclopentyl}acetyl)-L-Isoleucine

C18H29NO4 (323.2096)


   

Procyclidine hydrochloride

Procyclidine hydrochloride

C19H30ClNO (323.2016)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy[1][2].

   

N,N-bis(2-hydroxyethyl)-N-methyldodecan-1-aminium chloride

N,N-bis(2-hydroxyethyl)-N-methyldodecan-1-aminium chloride

C17H38ClNO2 (323.2591)


   

3-N-BOC-AMINO-1-[2-AMINO-1-(3-FLUORO-PHENYL)-ETHYL]-PYRROLIDINE

3-N-BOC-AMINO-1-[2-AMINO-1-(3-FLUORO-PHENYL)-ETHYL]-PYRROLIDINE

C17H26FN3O2 (323.2009)


   

3-N-BOC-AMINO-1-[2-AMINO-1-(4-FLUORO-PHENYL)-ETHYL]-PYRROLIDINE

3-N-BOC-AMINO-1-[2-AMINO-1-(4-FLUORO-PHENYL)-ETHYL]-PYRROLIDINE

C17H26FN3O2 (323.2009)


   

N-Benzyl-4-carbamyl-4-(p-toluidino)-piperidine

N-Benzyl-4-carbamyl-4-(p-toluidino)-piperidine

C20H25N3O (323.1998)


   

Bufetolol

Bufetolol

C18H29NO4 (323.2096)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists

   

Cicloprolol

1-[4-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-3-(propan-2-ylamino)propan-2-ol

C18H29NO4 (323.2096)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist

   

N5-(1-CYCLOHEPTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)PYRIDINE-2,5-DIAMINE

N5-(1-CYCLOHEPTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)PYRIDINE-2,5-DIAMINE

C17H21N7 (323.1858)


   

(±)-Octanoylcarnitine chloride

(±)-Octanoylcarnitine chloride

C15H30ClNO4 (323.1863)


   

tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,6,7-tetrahydroazepine-1-carboxylate

tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,6,7-tetrahydroazepine-1-carboxylate

C17H30BNO4 (323.2268)


   

tert-Butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)carbamate

tert-Butyl (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)carbamate

C17H30BNO4 (323.2268)


   

Guaiapate

Guaiapate

C18H29NO4 (323.2096)


C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent

   
   

p-ethoxybenzylidene p-heptylaniline

p-ethoxybenzylidene p-heptylaniline

C22H29NO (323.2249)


   

Cinnamaverine

Cinnamaverine

C21H25NO2 (323.1885)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   

(2-hydroxypropyl)ammonium phosphate

(2-hydroxypropyl)ammonium phosphate

C9H30N3O7P (323.1821)


   

Olopatadine Methanol

Olopatadine Methanol

C21H25NO2 (323.1885)


   

2-[3-(3-hydroxyphenyl)-2,3-dimethylpiperidin-1-yl]-1-phenylethanone

2-[3-(3-hydroxyphenyl)-2,3-dimethylpiperidin-1-yl]-1-phenylethanone

C21H25NO2 (323.1885)


   

5-(tetrahydro-2H-pyran-4-yloxy)pyridine-3-boronic acid pinacol ester

5-(tetrahydro-2H-pyran-4-yloxy)pyridine-3-boronic acid pinacol ester

C16H26BNO5 (323.1904)


   

5-AMINOMETHYL-2-(N,N-DITERT-BUTOXYCARBONYLAMINO)PYRIDINE

5-AMINOMETHYL-2-(N,N-DITERT-BUTOXYCARBONYLAMINO)PYRIDINE

C16H25N3O4 (323.1845)


   

3-Amino-3-(hydroxymethyl)-1-(4-octylphenyl)-1,4-butanediol

3-Amino-3-(hydroxymethyl)-1-(4-octylphenyl)-1,4-butanediol

C19H33NO3 (323.246)


   

Venlafaxine-d10 hydrochloride

Venlafaxine-d10 hydrochloride

C17H18ClD10NO2 (323.2436)


   

N-Benzyl-1-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine

N-Benzyl-1-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine

C20H26BNO2 (323.2056)


   

4-Butoxybenzylidene-4-pentylaniline

4-Butoxybenzylidene-4-pentylaniline

C22H29NO (323.2249)


   

Tris(2-(2-methoxyethoxy)ethyl)amine

Tris(2-(2-methoxyethoxy)ethyl)amine

C15H33NO6 (323.2308)


   
   

Ethyl 1-benzyl-4-phenylpiperidine-4-carboxylate

Ethyl 1-benzyl-4-phenylpiperidine-4-carboxylate

C21H25NO2 (323.1885)


   

1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine

1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine

C21H25NO2 (323.1885)


   

N-({(1r,2s)-3-Oxo-2-[(2z)-Pent-2-En-1-Yl]cyclopentyl}acetyl)-L-Isoleucine

N-({(1r,2s)-3-Oxo-2-[(2z)-Pent-2-En-1-Yl]cyclopentyl}acetyl)-L-Isoleucine

C18H29NO4 (323.2096)


   

Cycrimine hydrochloride

Cycrimine hydrochloride

C19H30ClNO (323.2016)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent

   

4-[[Bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol

4-[[Bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol

C19H33NO3 (323.246)


   

Lysergide-D3; LSD-D3; Lysergic Acid Diethylamide-D3

Lysergide-D3; LSD-D3; Lysergic Acid Diethylamide-D3

C20H25N3O (323.1998)


   

Ethanaminium, N-[6-(diethylamino)-3H-xanthen-3-ylidene]-N-ethyl-, chloride

Ethanaminium, N-[6-(diethylamino)-3H-xanthen-3-ylidene]-N-ethyl-, chloride

C21H27N2O+ (323.2123)


   

(2S)-2-amino-1-[(2S)-2-(aminomethyl)pyrrolidin-1-yl]-3-(4-phenylphenyl)propan-1-one

(2S)-2-amino-1-[(2S)-2-(aminomethyl)pyrrolidin-1-yl]-3-(4-phenylphenyl)propan-1-one

C20H25N3O (323.1998)


   

Prodigiosine

Prodigiosine

C20H25N3O (323.1998)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents

   

3-Farnesylindole

3-Farnesylindole

C23H33N (323.2613)


   

dihydromonacolin L carboxylate

dihydromonacolin L carboxylate

C19H31O4- (323.2222)


A hydroxy monocarboxylic acid anion that is the conjugate base of dihydromonacolin L acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

2-(8-hydroxy-2-oxotridecyl)-6-oxopyran-4-olate

2-(8-hydroxy-2-oxotridecyl)-6-oxopyran-4-olate

C18H27O5- (323.1858)


   

N-[2-[3-oxo-2-(2Z)-2-penten-1-yl-cyclopentyl]acetyl]-L-isoleucine

N-[2-[3-oxo-2-(2Z)-2-penten-1-yl-cyclopentyl]acetyl]-L-isoleucine

C18H29NO4 (323.2096)


   

(11Z,17Z)-14R-hydroxy-eicosa-11,17-dienoate

(11Z,17Z)-14R-hydroxy-eicosa-11,17-dienoate

C20H35O3- (323.2586)


   

4-methyl-2-[[2-[(1R,2R)-3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]pentanoic acid

4-methyl-2-[[2-[(1R,2R)-3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]pentanoic acid

C18H29NO4 (323.2096)


   

(2S)-4-methyl-2-[[2-[3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]pentanoic acid

(2S)-4-methyl-2-[[2-[3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]pentanoic acid

C18H29NO4 (323.2096)


   

(2E,4E,7R)-11-[(2R,3R)-3-(hydroxymethyl)-4-oxooxetan-2-yl]-3,5,7-trimethylundeca-2,4-dienoate

(2E,4E,7R)-11-[(2R,3R)-3-(hydroxymethyl)-4-oxooxetan-2-yl]-3,5,7-trimethylundeca-2,4-dienoate

C18H27O5- (323.1858)


   

Undeca-2,4,6-trienoylcarnitine

Undeca-2,4,6-trienoylcarnitine

C18H29NO4 (323.2096)


   

Undeca-2,5,8-trienoylcarnitine

Undeca-2,5,8-trienoylcarnitine

C18H29NO4 (323.2096)


   

Undeca-3,5,7-trienoylcarnitine

Undeca-3,5,7-trienoylcarnitine

C18H29NO4 (323.2096)


   

(4E,6E)-Undeca-4,6,9-trienoylcarnitine

(4E,6E)-Undeca-4,6,9-trienoylcarnitine

C18H29NO4 (323.2096)


   

3-Methoxy-2-[(5-methylidene-4-pentylpyrrol-2-ylidene)methyl]-5-(1H-pyrrol-2-yl)-1H-pyrrole

3-Methoxy-2-[(5-methylidene-4-pentylpyrrol-2-ylidene)methyl]-5-(1H-pyrrol-2-yl)-1H-pyrrole

C20H25N3O (323.1998)


   

1-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-3-(4-ethylphenyl)urea

1-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-3-(4-ethylphenyl)urea

C20H25N3O (323.1998)


   

2-[(Dimethylamino)methyl]-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1-cyclohexane]one

2-[(Dimethylamino)methyl]-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1-cyclohexane]one

C20H25N3O (323.1998)


   

N,N-diethyl-4-[oxo-(2,4,6-trimethylphenyl)methyl]benzamide

N,N-diethyl-4-[oxo-(2,4,6-trimethylphenyl)methyl]benzamide

C21H25NO2 (323.1885)


   

1-[4-[4-[(4-Methylphenyl)methylamino]phenyl]-1-piperazinyl]ethanone

1-[4-[4-[(4-Methylphenyl)methylamino]phenyl]-1-piperazinyl]ethanone

C20H25N3O (323.1998)


   

ML-236A carboxylate

ML-236A carboxylate

C18H27O5- (323.1858)


   

1-[4-[4-[(3-Methylphenyl)methylamino]phenyl]-1-piperazinyl]ethanone

1-[4-[4-[(3-Methylphenyl)methylamino]phenyl]-1-piperazinyl]ethanone

C20H25N3O (323.1998)


   

3,4-dimethyl-N-[4-(4-methyl-1-piperazinyl)phenyl]benzamide

3,4-dimethyl-N-[4-(4-methyl-1-piperazinyl)phenyl]benzamide

C20H25N3O (323.1998)


   

1-(Pyrrolidin-1-yl)propan-2-yl diphenylacetate

1-(Pyrrolidin-1-yl)propan-2-yl diphenylacetate

C21H25NO2 (323.1885)


   

2,2,7,7,9,9-hexamethyl-10-oxido-8H-pyrano[2,3-b]carbazol-10-ium

2,2,7,7,9,9-hexamethyl-10-oxido-8H-pyrano[2,3-b]carbazol-10-ium

C21H25NO2 (323.1885)


   

(+-)-Procyclidine hydrochloride

(+-)-Procyclidine hydrochloride

C19H30ClNO (323.2016)


   

(S)-cycrimine hydrochloride

(S)-cycrimine hydrochloride

C19H30ClNO (323.2016)


   

(R)-cycrimine hydrochloride

(R)-cycrimine hydrochloride

C19H30ClNO (323.2016)


   

(Z,Z)-dicyclopropyl-oxomycolate

(Z,Z)-dicyclopropyl-oxomycolate

C19H31O4- (323.2222)


   

N-({(1R)-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl}acetyl)-L-isoleucine

N-({(1R)-3-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl}acetyl)-L-isoleucine

C18H29NO4 (323.2096)


   

(15S)-hydroxy-(11Z,13E)-eicosadienoate

(15S)-hydroxy-(11Z,13E)-eicosadienoate

C20H35O3- (323.2586)


   

N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]acetamide

N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]acetamide

C19H33NO3 (323.246)


   

N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]propanamide

N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]propanamide

C19H33NO3 (323.246)


   

N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]butanamide

N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]butanamide

C19H33NO3 (323.246)


   

N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]pentanamide

N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]pentanamide

C19H33NO3 (323.246)


   

(-)-Jasmonoyl-L-isoleucine

(-)-Jasmonoyl-L-isoleucine

C18H29NO4 (323.2096)


   

N-[(+)-7-isojasmonyl]-L-isoleucine

N-[(+)-7-isojasmonyl]-L-isoleucine

C18H29NO4 (323.2096)


An L-isoleucine derivative resulting from the formal condensation of the carboxy group of (+)-7-isojasmonic acid with the amino group of L-isoleucine.

   

D-Lysergic acid N,N-diethylamide

D-Lysergic acid N,N-diethylamide

C20H25N3O (323.1998)


   

Lysergic acid diethylamide

Lysergic acid diethylamide

C20H25N3O (323.1998)


An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.

   

NA-Gly 17:2(9Z,12Z)

NA-Gly 17:2(9Z,12Z)

C19H33NO3 (323.246)


   
   
   

S3QEL-2

S3QEL-2

C19H25N5 (323.211)


S3QEL-2, a suppressor of superoxide production from mitochondrial complex III, potently and selectively suppresses site IIIQo superoxide production (IC50=1.7 μM). S3QEL-2 does not affect oxidative phosphorylation, and normal electron flux. S3QEL-2 inhibits HIF-1α accumulation[1].

   

(3r,5s,7ar,11as)-3-(chloromethyl)-5-hexyl-1h,2h,3h,5h,6h,7h,7ah,11h-pyrrolo[2,1-j]quinolin-10-one

(3r,5s,7ar,11as)-3-(chloromethyl)-5-hexyl-1h,2h,3h,5h,6h,7h,7ah,11h-pyrrolo[2,1-j]quinolin-10-one

C19H30ClNO (323.2016)


   

(1s,5r)-1-(butanoyloxy)-6,8-dimethyl-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

(1s,5r)-1-(butanoyloxy)-6,8-dimethyl-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

C18H29NO4 (323.2096)


   

8-(8-hydroxy-8-methyl-hexahydroindolizin-6-ylidene)-4,7-dimethyloct-4-ene-2,3-diol

8-(8-hydroxy-8-methyl-hexahydroindolizin-6-ylidene)-4,7-dimethyloct-4-ene-2,3-diol

C19H33NO3 (323.246)


   

(2s,3r)-2-({1-hydroxy-2-[(1r,2s)-3-oxo-2-[(2z)-pent-2-en-1-yl]cyclopentyl]ethylidene}amino)-3-methylpentanoic acid

(2s,3r)-2-({1-hydroxy-2-[(1r,2s)-3-oxo-2-[(2z)-pent-2-en-1-yl]cyclopentyl]ethylidene}amino)-3-methylpentanoic acid

C18H29NO4 (323.2096)


   

n-(1,3-dihydroxy-3-methyl-4-oxopentan-2-yl)-6,8-dimethyldeca-2,4,6-trienamide

n-(1,3-dihydroxy-3-methyl-4-oxopentan-2-yl)-6,8-dimethyldeca-2,4,6-trienamide

C18H29NO4 (323.2096)


   

methyl 1-[(dimethylamino)methyl]-3a-hydroxy-5-isopropyl-7a-methyl-7-oxo-1,2,3,4-tetrahydroindene-4-carboxylate

methyl 1-[(dimethylamino)methyl]-3a-hydroxy-5-isopropyl-7a-methyl-7-oxo-1,2,3,4-tetrahydroindene-4-carboxylate

C18H29NO4 (323.2096)


   

2-({1-hydroxy-2-[3-oxo-2-(pent-2-en-1-yl)cyclopentyl]ethylidene}amino)-3-methylpentanoic acid

2-({1-hydroxy-2-[3-oxo-2-(pent-2-en-1-yl)cyclopentyl]ethylidene}amino)-3-methylpentanoic acid

C18H29NO4 (323.2096)


   

6-[(11r)-11-hydroxydodecyl]-3-methoxy-2-methyl-1h-pyridin-4-one

6-[(11r)-11-hydroxydodecyl]-3-methoxy-2-methyl-1h-pyridin-4-one

C19H33NO3 (323.246)


   

(3r,5r)-3-methyl-5-[(2r)-1-{4-[(2r,4r)-4-methyl-5-oxooxolan-2-yl]butyl}pyrrolidin-2-yl]oxolan-2-one

(3r,5r)-3-methyl-5-[(2r)-1-{4-[(2r,4r)-4-methyl-5-oxooxolan-2-yl]butyl}pyrrolidin-2-yl]oxolan-2-one

C18H29NO4 (323.2096)


   

(1s,5r)-8-methyl-6-[(2-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

(1s,5r)-8-methyl-6-[(2-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

C18H29NO4 (323.2096)


   

4-{[(1r,5r)-6,8-dimethyl-8-azabicyclo[3.2.1]octan-1-yl]oxy}-4-oxobutan-2-yl (2e)-2-methylbut-2-enoate

4-{[(1r,5r)-6,8-dimethyl-8-azabicyclo[3.2.1]octan-1-yl]oxy}-4-oxobutan-2-yl (2e)-2-methylbut-2-enoate

C18H29NO4 (323.2096)


   

(2r,3r,4e,7r)-8-[(6z,8s,8as)-8-hydroxy-8-methyl-hexahydroindolizin-6-ylidene]-4,7-dimethyloct-4-ene-2,3-diol

(2r,3r,4e,7r)-8-[(6z,8s,8as)-8-hydroxy-8-methyl-hexahydroindolizin-6-ylidene]-4,7-dimethyloct-4-ene-2,3-diol

C19H33NO3 (323.246)


   

n-{[6-(4,5-dimethyl-7-oxohepta-3,5-dien-1-yl)-3-hydroxy-5-methyloxan-2-yl]methyl}ethanimidic acid

n-{[6-(4,5-dimethyl-7-oxohepta-3,5-dien-1-yl)-3-hydroxy-5-methyloxan-2-yl]methyl}ethanimidic acid

C18H29NO4 (323.2096)


   

2-methyl-1-(6-methylheptyl)-9h-carbazole-3,4-dione

2-methyl-1-(6-methylheptyl)-9h-carbazole-3,4-dione

C21H25NO2 (323.1885)


   

(1r,3r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (1r,2s,3s,4s,5r)-3,4-dihydroxy-6,6-dimethylbicyclo[3.1.1]heptane-2-carboxylate

(1r,3r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (1r,2s,3s,4s,5r)-3,4-dihydroxy-6,6-dimethylbicyclo[3.1.1]heptane-2-carboxylate

C18H29NO4 (323.2096)


   

(2s,3r)-2-({1-hydroxy-2-[(1r,2r)-3-oxo-2-[(2z)-pent-2-en-1-yl]cyclopentyl]ethylidene}amino)-3-methylpentanoic acid

(2s,3r)-2-({1-hydroxy-2-[(1r,2r)-3-oxo-2-[(2z)-pent-2-en-1-yl]cyclopentyl]ethylidene}amino)-3-methylpentanoic acid

C18H29NO4 (323.2096)


   

3-(chloromethyl)-5-hexyl-1h,2h,3h,5h,6h,7h,7ah,11h-pyrrolo[2,1-j]quinolin-10-one

3-(chloromethyl)-5-hexyl-1h,2h,3h,5h,6h,7h,7ah,11h-pyrrolo[2,1-j]quinolin-10-one

C19H30ClNO (323.2016)


   

2-methyl-1-(5-methylheptyl)-9h-carbazole-3,4-dione

2-methyl-1-(5-methylheptyl)-9h-carbazole-3,4-dione

C21H25NO2 (323.1885)


   

methyl (2r,5s)-5-[(9r,9as)-3-oxo-octahydropyrrolo[1,2-a]azepin-9-yl]-2-methyl-4-oxoheptanoate

methyl (2r,5s)-5-[(9r,9as)-3-oxo-octahydropyrrolo[1,2-a]azepin-9-yl]-2-methyl-4-oxoheptanoate

C18H29NO4 (323.2096)


   

n-[2-hydroxy-1-(5-hydroxy-6-methyloxan-2-yl)pyrimidin-4-ylidene]-4-methylpentanamide

n-[2-hydroxy-1-(5-hydroxy-6-methyloxan-2-yl)pyrimidin-4-ylidene]-4-methylpentanamide

C16H25N3O4 (323.1845)


   

3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-2,3-dihydro-1h-indole

3-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-2,3-dihydro-1h-indole

C23H33N (323.2613)


   

3-(butanoyloxy)-6,8-dimethyl-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

3-(butanoyloxy)-6,8-dimethyl-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

C18H29NO4 (323.2096)


   

8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3,4-dihydroxy-6,6-dimethylbicyclo[3.1.1]heptane-2-carboxylate

8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3,4-dihydroxy-6,6-dimethylbicyclo[3.1.1]heptane-2-carboxylate

C18H29NO4 (323.2096)


   

(5e)-4-methoxy-5-[(5-methyl-4-pentyl-1h-pyrrol-2-yl)methylidene]-1'h-2,2'-bipyrrole

(5e)-4-methoxy-5-[(5-methyl-4-pentyl-1h-pyrrol-2-yl)methylidene]-1'h-2,2'-bipyrrole

C20H25N3O (323.1998)


   

(3r,5s)-3-methyl-5-[(2r)-1-{4-[(2r,4r)-4-methyl-5-oxooxolan-2-yl]butyl}pyrrolidin-2-yl]oxolan-2-one

(3r,5s)-3-methyl-5-[(2r)-1-{4-[(2r,4r)-4-methyl-5-oxooxolan-2-yl]butyl}pyrrolidin-2-yl]oxolan-2-one

C18H29NO4 (323.2096)


   

methyl 2-methyl-4-oxo-5-{3-oxo-octahydropyrrolo[1,2-a]azepin-9-yl}heptanoate

methyl 2-methyl-4-oxo-5-{3-oxo-octahydropyrrolo[1,2-a]azepin-9-yl}heptanoate

C18H29NO4 (323.2096)


   

4-methoxy-5-[(5-methyl-4-pentyl-1h-pyrrol-2-yl)methylidene]-1'h-2,2'-bipyrrole

4-methoxy-5-[(5-methyl-4-pentyl-1h-pyrrol-2-yl)methylidene]-1'h-2,2'-bipyrrole

C20H25N3O (323.1998)


   

(2e,4e,6e)-n-[(2r,3s)-1,3-dihydroxy-3-methyl-4-oxopentan-2-yl]-6,8-dimethyldeca-2,4,6-trienimidic acid

(2e,4e,6e)-n-[(2r,3s)-1,3-dihydroxy-3-methyl-4-oxopentan-2-yl]-6,8-dimethyldeca-2,4,6-trienimidic acid

C18H29NO4 (323.2096)


   

4-methoxy-5-{[(2z)-5-methyl-4-pentylpyrrol-2-ylidene]methyl}-1h,1'h-2,2'-bipyrrole

4-methoxy-5-{[(2z)-5-methyl-4-pentylpyrrol-2-ylidene]methyl}-1h,1'h-2,2'-bipyrrole

C20H25N3O (323.1998)


   

4-(4-aminocyclohexa-2,5-dien-1-yl)-2-{[1-hydroxy-3-methyl-2-(methylamino)pentylidene]amino}butanoic acid

4-(4-aminocyclohexa-2,5-dien-1-yl)-2-{[1-hydroxy-3-methyl-2-(methylamino)pentylidene]amino}butanoic acid

C17H29N3O3 (323.2209)


   

methyl (1r,3as,4r,7ar)-1-[(dimethylamino)methyl]-3a-hydroxy-5-isopropyl-7a-methyl-7-oxo-1,2,3,4-tetrahydroindene-4-carboxylate

methyl (1r,3as,4r,7ar)-1-[(dimethylamino)methyl]-3a-hydroxy-5-isopropyl-7a-methyl-7-oxo-1,2,3,4-tetrahydroindene-4-carboxylate

C18H29NO4 (323.2096)


   

n-{2-hydroxy-1-[(2r,5s,6r)-5-hydroxy-6-methyloxan-2-yl]pyrimidin-4-ylidene}-4-methylpentanamide

n-{2-hydroxy-1-[(2r,5s,6r)-5-hydroxy-6-methyloxan-2-yl]pyrimidin-4-ylidene}-4-methylpentanamide

C16H25N3O4 (323.1845)


   

2-[(11s)-11-hydroxydodecyl]-3-methoxy-6-methyl-1h-pyridin-4-one

2-[(11s)-11-hydroxydodecyl]-3-methoxy-6-methyl-1h-pyridin-4-one

C19H33NO3 (323.246)


   

2-(11-hydroxydodecyl)-3-methoxy-6-methyl-1h-pyridin-4-one

2-(11-hydroxydodecyl)-3-methoxy-6-methyl-1h-pyridin-4-one

C19H33NO3 (323.246)


   

8-methyl-6-[(2-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

8-methyl-6-[(2-methylbutanoyl)oxy]-8-azabicyclo[3.2.1]octan-3-yl (2e)-2-methylbut-2-enoate

C18H29NO4 (323.2096)


   

3-methyl-5-{1-[4-(4-methyl-5-oxooxolan-2-yl)butyl]pyrrolidin-2-yl}oxolan-2-one

3-methyl-5-{1-[4-(4-methyl-5-oxooxolan-2-yl)butyl]pyrrolidin-2-yl}oxolan-2-one

C18H29NO4 (323.2096)


   

(2r,3r,4e)-8-[(6z,8s,8as)-8-hydroxy-8-methyl-hexahydroindolizin-6-ylidene]-4,7-dimethyloct-4-ene-2,3-diol

(2r,3r,4e)-8-[(6z,8s,8as)-8-hydroxy-8-methyl-hexahydroindolizin-6-ylidene]-4,7-dimethyloct-4-ene-2,3-diol

C19H33NO3 (323.246)


   

(z,5z)-4-methoxy-5-[(5-methyl-4-pentyl-1h-pyrrol-2-yl)methylidene]-1h-2,2'-bipyrrolylidene

(z,5z)-4-methoxy-5-[(5-methyl-4-pentyl-1h-pyrrol-2-yl)methylidene]-1h-2,2'-bipyrrolylidene

C20H25N3O (323.1998)


   

(2s,3s,4z,7r)-8-[(6z,8s,8as)-8-hydroxy-8-methyl-hexahydroindolizin-6-ylidene]-4,7-dimethyloct-4-ene-2,3-diol

(2s,3s,4z,7r)-8-[(6z,8s,8as)-8-hydroxy-8-methyl-hexahydroindolizin-6-ylidene]-4,7-dimethyloct-4-ene-2,3-diol

C19H33NO3 (323.246)


   

n-{[(2s,3r,5r,6r)-6-[(3e,5e)-4,5-dimethyl-7-oxohepta-3,5-dien-1-yl]-3-hydroxy-5-methyloxan-2-yl]methyl}ethanimidic acid

n-{[(2s,3r,5r,6r)-6-[(3e,5e)-4,5-dimethyl-7-oxohepta-3,5-dien-1-yl]-3-hydroxy-5-methyloxan-2-yl]methyl}ethanimidic acid

C18H29NO4 (323.2096)


   

2-methyl-1-[(5s)-5-methylheptyl]-9h-carbazole-3,4-dione

2-methyl-1-[(5s)-5-methylheptyl]-9h-carbazole-3,4-dione

C21H25NO2 (323.1885)